Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.
Medscape Medical News

source https://www.medscape.com/viewarticle/phase-3-palopegteriparatide-results-show-sustained-benefits-2026a1000jyi?src=rss